TITAN PHARMACEUTICALS INC (TTNP) is a publicly traded company in the Unknown sector. Across all available filings, 14 corporate insiders have executed 39 transactions totaling $11.7M, demonstrating a bearish sentiment with -$6.7M in net insider flow. The most recent transaction on Oct 1, 2025 involved a transaction of 3,313 shares valued at $0.
No significant insider buying has been recorded for TTNP in the recent period.
No significant insider selling has been recorded for TTNP in the recent period.
Based on recent SEC filings, insider sentiment for TTNP is bearish with an Insider Alignment Score of 21/100 and a net flow of -$6.7M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at TITAN PHARMACEUTICALS INC (TTNP) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 14 insiders are actively trading TTNP stock, having executed 39 transactions in the past 90 days. The most active insider is Investing Llc Activist (Executive), who has made 6 transactions totaling $9.3M.
Get notified when executives and directors at TTNP file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Oct 1, 2025 | Ben-tzvi Avraham | Executive | Disposition | 3,313 | $N/A | $0 | |
| Mar 18, 2024 | Hau Choong Choon | Executive | Conversion | 54,132 | $N/A | $0 | |
| Oct 25, 2023 | Ben-tzvi Avraham | Executive | Award | 16,250 | $N/A | $0 | |
| Oct 25, 2023 | Beebe Katherine | Executive | Award | 16,250 | $N/A | $0 | |
| Oct 25, 2023 | Howard Greenberg Eric | Executive | Award | 16,250 | $N/A | $0 | |
| Oct 25, 2023 | Charles Mcmurdo Matthew | Executive | Award | 16,250 | $N/A | $0 | |
| Oct 25, 2023 | Natan David | Executive | Award | 16,250 | $N/A | $0 | |
| Jul 26, 2023 | Natan David | Executive | Award | 50,000 | $N/A | $0 | |
| Jul 26, 2023 | Charles Mcmurdo Matthew | Executive | Award | 50,000 | $N/A | $0 | |
| Jul 26, 2023 | Beebe Katherine | Executive | Award | 50,000 | $N/A | $0 | |
| Jul 26, 2023 | Louis Chasey Peter | Executive | Award | 50,000 | $N/A | $0 | |
| Jul 26, 2023 | Ben-tzvi Avraham | Executive | Award | 50,000 | $N/A | $0 | |
| Jul 26, 2023 | E. Lazar David | Executive | Award | 100,000 | $N/A | $0 | |
| Jul 26, 2023 | Charles Mcmurdo Matthew | Executive | Award | 50,000 | $N/A | $0 | |
| Jul 26, 2023 | Louis Chasey Peter | Executive | Award | 50,000 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 4 | $9.2M | 78.5% |
Purchase(P) | 17 | $2.5M | 21.5% |
Disposition(D) | 1 | $0 | 0.0% |
Conversion(C) | 1 | $0 | 0.0% |
Award(A) | 15 | $0 | 0.0% |
Other(J) | 1 | $0 | 0.0% |
Insider selling pressure at TITAN PHARMACEUTICALS INC has increased, with 14 insiders executing 39 transactions across all time. Total sales of $9.2M significantly outpace purchases of $2.5M, resulting in a net outflow of $6.7M. This selling activity appears largely discretionary, which may warrant closer attention from investors.